Results 241 to 250 of about 13,000,271 (286)

The impact of capping health system cost savings on the projected cost-effectiveness of etranacogene dezaparvovec compared with factor IX prophylaxis for the treatment of hemophilia B. [PDF]

J Manag Care Spec Pharm
Sarker J, Tice JA, Rind DM, Pearson SD, Walton SM.   +4 more
europepmc   +1 more source

Human umbilical cord mesenchymal stem cell-based gene therapy for hemophilia B using scAAV-DJ/8-LP1-hFIXco transduction. [PDF]

Stem Cell Res Ther
Bu Z, Lou J, Xu W, Zhang L, Tang Y.
europepmc   +1 more source

Images of Temporomandibular Joint Arthropathy in Patient with Severe Hemophilia B with Inhibitor and Patient with Type III von Willebrand Disease with Inhibitor [PDF]

Turk J Haematol
Yenel S, Çankal DA, Akarslan Z, Yazol M, Kaya Z.   +4 more
europepmc   +1 more source

Nonacog beta pegol prophylaxis in children with hemophilia B: safety, efficacy, and neurodevelopmental outcomes for up to 8 years. [PDF]

Res Pract Thromb Haemost
Walsh KS, Mrakotsky C, Carcao M, Chan AKC, Nielsen PH, Holst H, Shapiro K.   +6 more
europepmc   +1 more source

A Post-Authorization Safety Surveillance Study to Report Clinical Experience with Purified Factor IX Concentrate in Pediatric Patients with Hemophilia B. [PDF]

J Blood Med
Igrutinović Z, Hooimeijer HL, Kentouche K, Botha J, Turecek PL, Kokot-Kierepa M, Gazda HT.   +6 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Inhibitors in Hemophilia B

Seminars in Thrombosis and Hemostasis, 2018
AbstractHemophilia B (HB) is an X-linked bleeding disorder caused by deficiency of factor IX (FIX). Patients with the severe form (FIX <1%) account approximately for 30 to 45% of persons with HB and usually suffer from recurrent joint, soft-tissue, and muscle bleeds.
Erminia Baldacci, Annarita Tagliaferri, Giancarlo Castaman, Gabriele Quintavalle, Federica Riccardi, Cristina Santoro, Antonietta Ferretti   +6 more
openaire   +4 more sources